Lung Cancer News

The combination of nivolumab and ipilimumab showed a promising rate of 12-week disease control among patients with recurrent malignant pleural mesothelioma, according to interim results of a phase 2 study presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

The addition of a smoking cessation intervention to a low-dose CT lung cancer screening program appeared cost-effective, according to data presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

The FDA granted priority review to durvalumab for the treatment of patients with locally advanced unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.

Socioeconomic factors, such as lower education and median income, significantly influenced survival among patients with non-small cell lung cancer, according to study results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Early palliative care did not significantly improve quality-of-life measures among patients newly diagnosed with malignant pleural mesothelioma, according to results of the RESPECT-MESO trial presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

The FDA granted priority review to a supplemental new drug application that seeks approval of afatinib for first-line treatment of certain patients with metastatic non-small cell lung cancer.

A phase 3 trial designed to evaluate abemaciclib monotherapy for KRAS-mutated advanced non-small lung cancer failed to meet its primary endpoint of improved OS, according to the drug’s manufacturer.

The FDA granted breakthrough therapy designation to osimertinib for the first-line treatment of patients with metastatic epidermal growth factor receptor-positive non-small cell lung cancer, according to the drug’s manufacturer.

Carefully selected patients with malignant pleural mesothelioma benefited from a surgery-based treatment modality, according to results from a propensity score matching analysis published in Journal of Clinical Oncology.

Consolidative stereotactic ablative radiotherapy before maintenance chemotherapy nearly tripled PFS among patients with limited metastatic non-small cell lung cancer, according to study results presented at the American Society for Radiation Oncology Annual Meeting.